Monocyte HLA-DR monitoring to detect immune weakness in severe intra-abdominal infections at risk for fungal invasion
Official title: Evaluation of the Innate Immune Response Through Monocyte HLA-DR Monitoring During Severe Intra-abdominal Candidiasis in the Critically Ill Patients
Run by Central Hospital, Nancy, France · NCT07130799 · Data updated 2026-11-12
This will test whether measuring monocyte HLA-DR can reveal innate immune weakness in adult ICU patients with severe intra‑abdominal infections who are at risk for invasive Candida.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Status | Recruiting |
| Started | November 14, 2025 |
| Main results expected | September 1, 2026 |
| Study ends | March 1, 2027 |
| Registry record updated | February 9, 2026 |
| Trial ID | NCT07130799 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) admitted to ICU or intermediate care for severe intra‑abdominal infection requiring urgent abdominal surgery who have one or more risk factors for intra‑abdominal candidiasis or a high peritonitis score are ideal candidates.
✕Probably not a fit
Patients who are not critically ill, managed without surgery (e.g., radiologic drainage only), moribund with expected imminent death, or those without risk factors for intra‑abdominal candidiasis are unlikely to gain direct benefit from this observational monitoring.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational immunomonitoring protocol enrolling adult ICU patients undergoing urgent surgery for severe intra‑abdominal infection and at least one risk factor for intra‑abdominal candidiasis. Blood samples will be taken to measure monocyte HLA‑DR expression as a marker of innate immune function and compared between patients who develop intra‑abdominal candidiasis and those with severe bacterial intra‑abdominal infections. The aim is to determine whether a deeper or more prolonged drop in HLA‑DR is associated with invasive fungal infection, which could inform earlier risk stratification. No investigational drug is given; the study uses laboratory immune profiling alongside routine clinical care.
Why it matters
Potential benefit: If successful, the findings could enable earlier identification of patients at high risk for invasive Candida and guide more timely antifungal or supportive interventions.
How similar studies have gone: Previous critical‑care studies have shown that low monocyte HLA‑DR correlates with immune suppression and worse outcomes in sepsis, but its specific predictive value for intra‑abdominal candidiasis remains incompletely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥ 18 years old) * Patient admitted to the ICU or intermediate care unit for a severe intra-abdominal infection requiring urgent abdominal surgery * Presence of at least one risk factor for intra-abdominal candidiasis: * Abdominal surgery within the last 7 days * Supramesocolic gastrointestinal perforation * Healthcare-associated intra-abdominal infection * Community-acquired intra-abdominal infection in an immunocompromised patient\* * Intra-abdominal infection complicated by septic shock * Broad-spectrum antibiotic exposure within 72 hours prior to surgery * And/or a Peritonitis Score ≥ 3 out of 4 * Patient affiliated with or benefiting from a national health insurance system * Patient who has received full information about the clinical study Exclusion Criteria: * Radiologically guided drainage without surgery * Infected acute pancreatitis * Limitation or withdrawal of life-sustaining treatments * Moribund patient with an expected life expectancy \< 48 hours * Woman of childbearing potential without effective contraception * Refusal to participate in the study
Where it's running
-
CHRU de NANCY
Vandœuvre-lès-Nancy, France Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Peripheral Perfusion Index trajectory to predict 28-day mortality in sepsis patients in the ICU
This study tests whether changes in a finger-based perfusion index over the first 24 hours in the ICU can predict 28-day death among adults with sepsis or septic shock.
-
Metabolic and Functional Study of γδ T Cells in Critically Ill Patients
Researchers will look at how γδ T cells behave in severely ill patients, including those with sepsis, to see how their metabolism and function change.
-
MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Help ICU Patients Maintain Muscle Strength
This trial tests whether adding daily 60-minute thigh electrical muscle stimulation to standard ICU care is safe and easy for adults with sepsis or critical illness to see if it slows ICU-acquired muscle weakness.
-
Hyperinflammation and High Ferritin in Critically Ill Patients
This study looks at critically ill patients with signs of high inflammation to see how their condition develops over time.
-
Investigating the gut microbiome's role in sepsis and brain function in critically ill patients
This study is trying to see how changes in gut bacteria from antibiotic use affect brain function and recovery in critically ill patients with severe infections or sepsis.
-
Effects of suctioning on pain and stress in intubated ICU patients
This study is testing if suctioning the breathing tube in ICU patients causes more pain and stress compared to not suctioning.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.